Tombolini V - Search Results

1

Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair.

Codenotti S, Marampon F, Triggiani L, Bonù ML, Magrini SM, Ceccaroli P, Guescini M, Gastaldello S, Tombolini V, Poliani PL, Asperti M, Poli M, Monti E, Fanzani A. Codenotti S, et al. Among authors: tombolini v. Cancer Lett. 2021 May 1;505:1-12. doi: 10.1016/j.canlet.2021.02.005. Epub 2021 Feb 18. Cancer Lett. 2021. PMID: 33610729

2

Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers.

Magrini SM, Ricardi U, Santoni R, Krengli M, Lupattelli M, Cafaro I, Scoccianti S, Menichelli C, Bertoni F, Enrici RM, Tombolini V, Buglione M, Pirtoli L. Magrini SM, et al. Among authors: tombolini v. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):788-99. doi: 10.1016/j.ijrobp.2006.01.026. Epub 2006 May 6. Int J Radiat Oncol Biol Phys. 2006. PMID: 16682131 Free article.

3

5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.

Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C. Gravina GL, et al. Among authors: tombolini v. Prostate. 2010 Aug;70(11):1166-78. doi: 10.1002/pros.21151. Prostate. 2010. PMID: 20333699

4

Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation.

Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, Tombolini V. Gravina GL, et al. Among authors: tombolini v. Mol Cancer. 2010 Nov 25;9:305. doi: 10.1186/1476-4598-9-305. Mol Cancer. 2010. PMID: 21108789 Free PMC article. Review.

5

MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, Pestell RG, Tombolini V, Zani BM. Marampon F, et al. Among authors: tombolini v. Mol Cancer Ther. 2011 Jan;10(1):159-68. doi: 10.1158/1535-7163.MCT-10-0631. Mol Cancer Ther. 2011. PMID: 21220498 Free PMC article.

6

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.

Gravina GL, Marampon F, Piccolella M, Biordi L, Ficorella C, Motta M, Jannini EA, Tombolini V, Festuccia C. Gravina GL, et al. Among authors: tombolini v. Prostate. 2011 Oct 1;71(14):1481-91. doi: 10.1002/pros.21363. Epub 2011 Mar 28. Prostate. 2011. PMID: 21446006

7

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

Gravina GL, Marampon F, Petini F, Biordi L, Sherris D, Jannini EA, Tombolini V, Festuccia C. Gravina GL, et al. Among authors: tombolini v. Endocr Relat Cancer. 2011 Jul 1;18(4):385-400. doi: 10.1530/ERC-11-0045. Print 2011 Aug. Endocr Relat Cancer. 2011. PMID: 21551258

8

Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.

Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, Jannini EA, Festuccia C. Gravina GL, et al. Among authors: tombolini v. Endocrinology. 2011 Dec;152(12):4550-61. doi: 10.1210/en.2011-1056. Epub 2011 Oct 11. Endocrinology. 2011. PMID: 21990314 Free PMC article.

9

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C. Gravina GL, et al. Among authors: tombolini v. Int J Oncol. 2012 Mar;40(3):711-20. doi: 10.3892/ijo.2011.1270. Epub 2011 Nov 23. Int J Oncol. 2012. PMID: 22134754

10

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.

Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C. Gravina GL, et al. Among authors: tombolini v. Endocr Relat Cancer. 2013 May 21;20(3):321-37. doi: 10.1530/ERC-12-0240. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23507703

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

301 results

Search Page